🩸 Early detection through simple blood tests enables the identification of islet autoantibodies, revealing the autoimmune activity associated with type 1 diabetes long before clinical symptoms appear. This creates new opportunities for monitoring, early intervention, and improved long-term outcomes.
EDENT1FI has established screening programs in several European countries. The project has implemented standardized testing for islet autoantibodies, harmonized data collection, and introduced central laboratories with rigorous quality control procedures, ensuring consistent and high-quality screening across Europe.
🌟 EDENT1FI aims to screen more than 220,000 children across Europe, further expanding early detection efforts and enabling timely access to preventive therapies such as Teplizumab, which has been shown to delay the onset of clinical type 1 diabetes.